NEW YORK (GenomeWeb) – The Flemish Government has awarded Biocartis a €1.7 million ($2.3 million) grant to build out the capabilities of the company's Idylla molecular diagnostics platform, Biocartis said today.
Biocartis said it will use the funding to further develop its hybrid multiplexing technology to detect and quantify multiple biomarker types on single Idylla tests. The company has developed oncology assays that can already detect tens of biomarkers of the same type.
"The hybrid multiplexing project will strengthen our competitive position in the oncology field and open new opportunities in other disease, such as infectious and genetic diseases," Biocartis CSO Geert Maertens said in a statement.
Earlier this month Biocartis and Abbott announced a collaboration to develop and commercialize companion diagnostic tests for use on the Idylla platform.